GHRP-2 cuts vascular oxidative stress in ApoE-/- mice but leaves atherosclerotic plaque unchanged
Background
Atherosclerosis remains a leading driver of cardiovascular mortality, with oxidized low-density lipoprotein (OxLDL) playing a central role in plaque initiation and progression. CD36, a scavenger receptor expressed on macrophages and smooth muscle cells, mediates cellular uptake of OxLDL and promotes foam-cell formation — a key early event in atherogenesis. Current lipid-lowering strategies incompletely address the vascular oxidative stress and inflammatory signaling that sustain plaque growth. GHRP-2 is a synthetic peptide known to stimulate GH and IGF-I secretion and has been identified as a ligand for CD36, raising the possibility it could competitively block OxLDL uptake and slow plaque development. Its dual action — endocrine and receptor-level — made it a mechanistically compelling candidate for antiatherogenic intervention.
Study Design
GHRP-2 at 20 µg twice daily was administered subcutaneously to ApoE(-/-) mice for 12 weeks, a well-validated model of diet-driven atherosclerosis. Primary endpoint was atherosclerotic plaque area; secondary endpoints included circulating IGF-I, interferon-gamma, and aortic superoxide production assessed by dihydroethidium staining. Aortic gene expression was profiled by qPCR for 12/15-lipoxygenase, interferon-gamma, and macrophage migration inhibitory factor. Complementary in vitro experiments used cultured aortic smooth muscle cells and macrophages challenged with OxLDL to assess peroxide generation, IGF-I receptor down-regulation, apoptosis, and lipid accumulation.
Results
GHRP-2 increased circulating IGF-I by 1.2- to 1.6-fold over the treatment period and decreased circulating interferon-gamma by 66%. Aortic superoxide production was reduced, as demonstrated by dihydroethidium staining, indicating meaningful suppression of vascular oxidative stress in vivo.
GHRP-2 decreased aortic gene expression of
12/15-lipoxygenaseby 92%, the single largest molecular effect observed in the study.
Aortic expression of both interferon-gamma and macrophage migration inhibitory factor was also reduced. In cultured aortic smooth muscle cells, GHRP-2 prevented OxLDL-induced peroxide generation, reversed down-regulation of the IGF-I receptor, and blocked apoptosis. In macrophages, GHRP-2 reduced lipid accumulation following OxLDL exposure. Despite these broad antioxidant and anti-inflammatory signals, atherosclerotic plaque area was not altered by GHRP-2 treatment in vivo.
Key Findings
- GHRP-2 20 µg SC twice daily did not reduce atherosclerotic plaque area in ApoE-/- mice after 12 weeks
- Circulating interferon-gamma decreased by 66% with GHRP-2 treatment
- Aortic 12/15-lipoxygenase gene expression fell by 92%
- Circulating IGF-I rose 1.2- to 1.6-fold over the treatment course
- GHRP-2 prevented OxLDL-induced apoptosis and peroxide generation in aortic smooth muscle cells in vitro
Why It Matters
The antioxidant and anti-inflammatory profile of GHRP-2 does not automatically translate into structural plaque regression — a critical distinction for anyone considering this peptide as a cardiovascular adjunct. The authors propose that GH-dependent effects in vivo may counteract the beneficial IGF-I-mediated actions, suggesting that the net in vivo balance is more complex than cell-culture data imply. For clinicians and advanced users stacking GHRP-2 with GHRH analogs, the GH-elevating arm of GHRP-2 may actively blunt its own vascular-protective potential, complicating protocol design. Translation to human cardiovascular endpoints remains distant; the null plaque result in a well-powered mouse model is a meaningful negative signal that should temper enthusiasm for using GHRP-2 primarily as an antiatherogenic agent.
